collaboration

Under the agreement, NeoGenomics will also make a $25 million equity investment in Inivata with an option to buy the company outright.

The companies are making three COVID-19 tools available immediately for early access, with plans to add other nCounter software and potentially develop new products.

The companies collaborated in Wuhan during the COVID-19 outbreak, using Darui's pathogenic microorganism detection kits on Genetron's next-generation sequencer.

The agreement marks Veracyte's first deal to expand the testing menu on the nCounter instrument since it acquired the rights to the platform from NanoString in December.

The firms are developing a kit-based CDx to detect NTRK gene fusions, including NTRK1, NTRK2 and NTRK3, for Bayer's Vitrakvi cancer treatment.

Regeneron will sequence and annotate 450,000 exomes and pair the data with UCHealth patient records to advance drug discovery and precision medicine.

The firms have already completed proof-of-concept studies for their semiconductor biosensor chips and Roswell plans to have the initial chips by 2021.

WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.

The two UK companies are validating GeneFirst's assay for use with Rapid Dx's Rapid Minilab RT-PCR Desktop Point of Care Platform.